Mbx Biosciences (MBX)Paradigm Biocapital Advisors LP opened a new position $138M

2.51M

Shares reported

2.6%

Disclosed portfolio weight

$138M

Reported value

Holdings as of

Jun 30, 2026

Filed

Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 9, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Departure of Chief Executive Officer Kent P. Hawryluk will be stepping away from his role as the Company’s Chief Executive Officer and end his services as a member of the Board effective as of July 13, 2026.”
2. Aug 6, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors (and 1 more item)

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Mbx Biosciences

For Mbx Biosciences, OQRO holds 5 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MBX page.

How this filing works

• SEC Form 13F

Other disclosures at Mbx Biosciences

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 15, 2026

Everything OQRO holds on this company is on its MBX page.